ZA200902203B - Combination therapy - Google Patents
Combination therapyInfo
- Publication number
- ZA200902203B ZA200902203B ZA200902203A ZA200902203A ZA200902203B ZA 200902203 B ZA200902203 B ZA 200902203B ZA 200902203 A ZA200902203 A ZA 200902203A ZA 200902203 A ZA200902203 A ZA 200902203A ZA 200902203 B ZA200902203 B ZA 200902203B
- Authority
- ZA
- South Africa
- Prior art keywords
- combination therapy
- therapy
- combination
- Prior art date
Links
- 238000002648 combination therapy Methods 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US85357206P | 2006-10-23 | 2006-10-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200902203B true ZA200902203B (en) | 2010-08-25 |
Family
ID=39324019
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200902203A ZA200902203B (en) | 2006-10-23 | 2007-10-23 | Combination therapy |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20100099762A1 (fr) |
| EP (1) | EP2076239A4 (fr) |
| JP (1) | JP2010507572A (fr) |
| AU (1) | AU2007308742A1 (fr) |
| CA (1) | CA2667052A1 (fr) |
| WO (1) | WO2008049157A1 (fr) |
| ZA (1) | ZA200902203B (fr) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040057983A1 (en) | 2002-09-25 | 2004-03-25 | David Schmidt | Biomolecular wearable apparatus |
| US8602961B2 (en) | 2008-05-15 | 2013-12-10 | Lifewave Products Llc | Apparatus and method of stimulating elevation of glutathione levels in a subject |
| US20130296430A1 (en) * | 2012-05-03 | 2013-11-07 | Antonio Hardan | Compositions and methods for treating autism and autism spectrum disorder |
| WO2016044314A1 (fr) * | 2014-09-15 | 2016-03-24 | Sound Pharmaceuticals Incorporated | Procédés et compositions pour le traitement de troubles psychotiques |
| BR112017025499A2 (pt) | 2015-05-28 | 2018-08-07 | Baylor College Medicine | benefícios da suplementação com n-acetil cisteína e glicina para melhorar os níveis de glutationa |
| EP3842040B1 (fr) * | 2016-01-11 | 2022-03-09 | Egetis Therapeutics AB | Méthodes et formulations pour le traitement et/ou la protection contre l'insuffisance hépatique aiguë, et autres troubles caractérisés par une hepatotoxicité |
| AU2020380291A1 (en) * | 2019-11-04 | 2022-05-26 | Neuronasal, Inc. | Use of magnetic resonance spectroscopy to calibrate and select doses, formulations, and devices for intra-nasal administration of N-acetylcysteine |
| KR102927722B1 (ko) * | 2020-05-09 | 2026-02-19 | 선전 프로파운드 뷰 파마슈티칼 테크놀로지 컴퍼니 리미티드 | 비정형 항정신병약물에 의해 유발되는 부작용의 치료 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6369106B1 (en) * | 1996-12-26 | 2002-04-09 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Treatment of ischemic brain injuries with brain targeted anti oxidant compounds |
| US20050032708A1 (en) * | 2001-09-27 | 2005-02-10 | Bush Ashley I. | Modulation of physiological processes and agents useful for same |
| WO2004069146A2 (fr) * | 2003-02-07 | 2004-08-19 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Derives d'amide l-dopa et utilisations de ceux-ci |
| US20060167068A1 (en) * | 2005-01-26 | 2006-07-27 | Seth Feuerstein | Method of treating self-injurious behavior with glutamate modulating agents |
| ES2564187T3 (es) * | 2005-04-05 | 2016-03-18 | Yale University | Agentes de modulación de glutamato en el tratamiento de trastornos mentales |
| US20090234011A1 (en) * | 2005-04-21 | 2009-09-17 | Goldstein Glenn A | N-acetylcysteine amide (nac amide) for the treatment of diseases and conditions associated with oxidative stress |
-
2007
- 2007-10-23 JP JP2009532650A patent/JP2010507572A/ja not_active Withdrawn
- 2007-10-23 WO PCT/AU2007/001611 patent/WO2008049157A1/fr not_active Ceased
- 2007-10-23 EP EP07815416A patent/EP2076239A4/fr not_active Withdrawn
- 2007-10-23 ZA ZA200902203A patent/ZA200902203B/xx unknown
- 2007-10-23 US US12/443,442 patent/US20100099762A1/en not_active Abandoned
- 2007-10-23 AU AU2007308742A patent/AU2007308742A1/en not_active Abandoned
- 2007-10-23 CA CA002667052A patent/CA2667052A1/fr not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP2076239A1 (fr) | 2009-07-08 |
| US20100099762A1 (en) | 2010-04-22 |
| EP2076239A4 (fr) | 2010-06-30 |
| AU2007308742A1 (en) | 2008-05-02 |
| CA2667052A1 (fr) | 2008-05-02 |
| JP2010507572A (ja) | 2010-03-11 |
| WO2008049157A1 (fr) | 2008-05-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL196559A0 (en) | Combination therapy | |
| GB0609492D0 (en) | Therapeutic agents | |
| GB2436010B (en) | Therapy device | |
| IL196556A0 (en) | Combination therapy | |
| GB0608928D0 (en) | Therapeutic agents | |
| IL199992A0 (en) | Combination therapy | |
| GB0601962D0 (en) | Therapeutic agents | |
| EP2054061A4 (fr) | Thérapie par combinaison | |
| GB0624874D0 (en) | Treatment | |
| GB0616214D0 (en) | Therapeutic Agents | |
| GB0719518D0 (en) | Therapy | |
| IL198026A0 (en) | Sequential combination therapy | |
| ZA200902203B (en) | Combination therapy | |
| GB0504206D0 (en) | Combination therapy | |
| GB0611152D0 (en) | Therapeutic agents | |
| EP2211863A4 (fr) | Polythérapie | |
| GB0620059D0 (en) | Therapeutic agents | |
| GB0700284D0 (en) | Combination therapy | |
| GB0620818D0 (en) | Therapeutic agents | |
| GB0609676D0 (en) | Therapeutic agents | |
| GB0700635D0 (en) | Therapy | |
| GB0604460D0 (en) | Treatment | |
| GB0716072D0 (en) | Therapy | |
| GB0606660D0 (en) | Targeted Therapy | |
| GB0622195D0 (en) | Therapeutic agents |